Atreca Inc - ESG Rating & Company Profile powered by AI
If you are employed by Atreca Inc and you wish to licence your Sustainability rating, please get in touch. The assessment of Atreca Inc is assembled by All Street Sevva using proprietary NLP. This assessment of Atreca Inc employs data from across the internet as well as from available disclosures by Atreca Inc.
Atreca Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.8; made up of an environmental score of 2.7, social score of 4.8 and governance score of 4.0.
3.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1089 | Zymeworks Inc | 3.9 | Medium |
| 1089 | bluebird bio Inc | 3.9 | Medium |
| 1112 | Atreca Inc | 3.8 | Medium |
| 1112 | AcelRx Pharmaceuticals Inc | 3.8 | Medium |
| 1112 | Arcus Biosciences Inc | 3.8 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Atreca Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Atreca Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Atreca Inc report the average age of the workforce?
Sign up for free to unlockDoes Atreca Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Atreca Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Atreca Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Atreca Inc offer flexible work?
Sign up for free to unlockDoes Atreca Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Atreca Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Atreca Inc conduct supply chain audits?
Sign up for free to unlockDoes Atreca Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Atreca Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Atreca Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Atreca Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Atreca Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Atreca Inc disclose water use targets?
Sign up for free to unlockDoes Atreca Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Atreca Inc have a product recall in the last two years?
Sign up for free to unlockDoes Atreca Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Atreca Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Atreca Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Atreca Inc disclose parental leave metrics?
Sign up for free to unlockDoes Atreca Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Atreca Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Atreca Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Atreca Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Atreca Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Atreca Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Atreca Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Atreca Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Atreca Inc disclose its waste policy?
Sign up for free to unlockDoes Atreca Inc report according to TCFD requirements?
Sign up for free to unlockDoes Atreca Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Atreca Inc disclose energy use targets?
Sign up for free to unlockDoes Atreca Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Atreca Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Atreca Inc
These potential risks are based on the size, segment and geographies of the company.
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.